Bicara Therapeutics (BCAX) Total Liabilities (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Total Liabilities of $39.6 million for Q1 2026, up 107.33% year-over-year from $19.1 million in Q1 2025, and up 34.19% quarter-over-quarter from $29.5 million in Q4 2025.
Bicara Therapeutics (BCAX) Total Liabilities (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Total Liabilities history runs 4 years deep, the most recent figure standing at $39.6 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 107.33% year-over-year to $39.6 million; the TTM figure through Mar 2026 stood at $39.6 million (up 107.33% YoY), while the FY2025 annual figure was $29.5 million, up 63.03% from the prior year.
- Total Liabilities for Q1 2026 stood at $39.6 million, up from $29.5 million in the prior quarter.
- The five-year high for Total Liabilities was $39.6 million in Q1 2026, with the low at $14.6 million in Q3 2024.
- The 4-year median for Total Liabilities is $18.8 million (2025), against an average of $22.1 million.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities gained 17.11% in 2024, then jumped 107.33% in 2026.
- Bicara Therapeutics' Total Liabilities stood at $15.5 million in 2023, then climbed by 17.11% to $18.1 million in 2024, then surged by 63.03% to $29.5 million in 2025, then surged by 34.19% to $39.6 million in 2026.
- Business Quant data shows BCAX's Total Liabilities at $39.6 million in Q1 2026, $29.5 million in Q4 2025, and $21.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 43.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.48 Mn |
| Mar 31, 2026 | 39.64 Mn |
| Dec 31, 2025 | 29.54 Mn |
| Sep 30, 2025 | 21.91 Mn |
| Jun 30, 2025 | 18.39 Mn |
| Mar 31, 2025 | 19.12 Mn |
| Dec 31, 2024 | 18.12 Mn |
| Sep 30, 2024 | 14.62 Mn |
| Dec 31, 2023 | 15.47 Mn |